Labomar S.p.A., a leading international nutraceutical company specialising in the research, development, and contract manufacturing of dietary supplements, medical devices, foods for special medical purposes, and cosmetics, announces the acquisition of 97.85% of the share capital of Pharmia Holding Oy, Finland’s leading CDMO (Contract Development and Manufacturing Organisation). Pharmia specialises in the development and production of dietary supplements, probiotics and medical devices. Labomar is backed by leading European private equity firm Charterhouse Capital Partners.
Founded in 1993, Pharmia now employs 85 people at its headquarters in Tuusula, just a few kilometres from Helsinki Airport, and operates a 5,000 m. integrated production site with an annual capacity of approx. 485 million tablets and capsules, and 37,000 litres of liquids.
With 2024 turnover of €20 million, further visible growth in 2025, a leading position in the Nordic countries (Finland, Sweden, Denmark and Norway) and extensive expertise in the development of probiotics and medical devices, the company consistently invests 5% of its turnover in research and development, continuing to strengthen operational efficiency and confirming itself as a strategic partner for numerous international players.
The transaction is Labomar Group’s fifth acquisition in six years, highlighting the company’s growth strategy, which has always been focused on innovation, the development of advanced health solutions and a diversified global presence. The acquisition of Pharmia Holding Oy will enable the company to continue to expand its expertise in research and development, particularly in medical devices and probiotics, and to benefit from a central position in a highpotential region, which has estimated* CAGR growth of 5-7% over the 2024-2029 period.
Expanding into the Nordic market will also enable Labomar to consolidate its international presence in nutraceuticals and medical devices, expanding its customer base and generating new synergies in terms of innovation and product development.
The transaction was finalised on September 25, with Pharmia’s current management remaining within the company and continuing to hold 2.15% of the company’s capital.
“Welcoming Pharmia into our Group is a source of great satisfaction and represents a key step in our vision for international growth,” stated Walter Bertin, founder and Chief Executive Officer of Labomar. “We have found a team that shares our approach to innovation and quality, allowing us to strengthen in a market full of opportunities, in which we can build lasting relationships with major players and accompany them in attaining increasingly advanced solutions. In addition, Pharmia’s solid management structure and production capacity will enable us to rapidly integrate activities and accelerate the development trajectory we are charting at a pan-European level”.
Antonio Di Lorenzo, Partner at Charterhouse Capital Partners, added, “We are very pleased to have supported the continued growth of Labomar over the past few years, both through organic expansion and through M&A opportunities, a key pillar of our value creation strategy.”
Petteri Laaksomo, CEO of Pharmia Holding Oy, commented, “We are thrilled to be part of the Labomar family. This acquisition marks a strategic step forward in our mission to expand our footprint in the Nordic region and strengthen our capabilities in the development of high-quality nutraceuticals and medical devices. Labomar’s expertise and values align seamlessly with ours, and together we look forward to driving innovation and delivering even greater value to our partners and customers”.
Labomar continues to pursue its acquisition-led growth strategy which begun in 2019, supported by Charterhouse Capital Partners and its value-creation capabilities, with the acquisition of Importfab (now Labomar Canada), which operates in the North American pharmaceutical, cosmetic and nutraceutical market; in 2020 with the entry of the Welcare Group, based in
Orvieto (Umbria) and specialising in medical devices for the prevention, hygiene and treatment of skin infections and lesions; of Labiotre, located in Tavarnelle Val di Pesa (Tuscany) and dedicated to the production of plant extracts and softgel dietary supplements; and finally of Laboratorios Entema, a Barcelona-based company specialising in the contract manufacturing of cosmetics, medical devices and dietary supplements.
The acquisition transaction was coordinated by an internal team comprising Claudio De Nadai (Board Member), Marco Malaguti (Chief Strategy Officer) and Nicola Tomasini (Group Chief Financial Officer).
Labomar was assisted in the acquisition by BModel as Corporate Advisor, which coordinated theprofessional activities dedicated to Business Due Diligence, carried out by Boston Consulting Group, for the Financial & Tax Due Diligence by EY Epyon, in addition to Legal Due Diligence, and the drafting of the legal and contractual documents by PwC Legal.
*Boston Consulting Group report
